Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

Rudick, RA; Stuart, WH; Calabresi, PA; Confavreux, C; Galetta, SL; Radue, EW; Lublin, FD; Weinstock-Guttman, B; Wynn, DR; Lynn, F; Panzara, MA; Sandrock, AW; Fazekas, F; Enzinger, C; Seifert, T; Storch, M; Strasser-Fuchs, S; Berger, T; Dilitz, E; Egg, R; Deisenhammer, F; Decoo, D; Lampaert, J; Bartholome, E; Bier, J; Stenager, E; Rasmussen, M; Binzer, M; Shorsh, K; Christensen, M; Ravnborg, M; Sorensen, PS; Blinkenberg, M; Petersen, B; Hansen, HJ; Bech, E; Petersen, T; Kirkegaard, M; Eralinna, J; Ruutiainen, J; Soilu-Hanninen, M; Sako, E; Laaksonen, M; Reunanen, M; Remes, A; Keskinarkaus, I; Moreau, T; Noblet, M; Rouaud, O; Couvreur, G; Edan, G; LePage, E; Drapier, S; De Burghgraeve, V; Yaouanq, J; Merienne, M; Cahagne, V; Gout, O; Deschamps, R; Le Canuet, P; Moulignier, A; Vermersch, P; De Seze, J; Stojkovic, T; Griffie, G; Engles, A; Ferriby, D; Debouverie, M; Pittion-Vouyouvitch, S; Lacour, JC; Pelletier, J; Feuillet, L; Suchet, L; Dalecky, A; Tammam, D; Lubetzki, C; Youssov, K; Mrejen, S; Charles, P; Yaici, S; Clavelou, P; Aufauvre, D; Renouil-Guy, N; Cesaro, P; Degos, F; Benisty, S; Rumbach, L; Decavel, P; Confavreux, C; Blanc, S; Aubertin, P; Riche, G; Brochet, B; Ouallet, JC; Anne, O; Menck, S; Grupe, A; Guttman, E; Lensch, E; Fucik, E; Heitmann, S; Hartung, HP; Schroter, M; Kurz, FMW; Heidenreich, F; Trebst, C; Pul, R; Hohlfeld, R; Krumbholz, M; Pellkofer, H; Haas, J; Segert, A; Anagnostou, P; Meyer, R; Kabus, C; Poehlau, D; Schneider, K; Hoffmann, V; Zettl, U; Steinhagen, V; Adler, S; Steinbrecher, A; Rothenfusser-Korber, E; Zellner, R; Baum, K; Gunther, A; Blasing, H; Stoll, G; Gold, R; Bayas, A; Kleinschnitz, C; Limmroth, V; Katsarava, Z; Kastrup, O; Haller, P; Stoeve, S; Hobel, D; Oschmann, P; Voigt, K; Burger, CV; Abramsky, O; Karusiss, D; Achiron, A; Kishner, I; Stern, Y; Sarove-Pinhas, I; Dolev, M; Magalashvili, D; Pozzili, C; Lenzi, D; Scontrini, A; Millefiorini, E; Buttinelli, C; Gallo, P; Ranzato, F; Tiberio, M; Perini, P; Laroni, A; Marrosu, M; Marchi, ECP; Spinicci, G; Massole, S; Mascia, M; Floris, G; Trojano, M; Bellacosa, A; Paolicelli, D; Zimatore, GB; Simone, IL; Giorelli, M; Di Monte, E; Mancardi, G; Pizzorno, M; Murialdo, A; Narciso, E; Capello, A; Comi, G; Martinelli, V; Rodegher, M; Esposito, F; Colombo, B; Rossi, P; Polman, CH; Jasperse, MMS; Zwemmer, JNP; Nielsen, J; Kragt, JJ; Jongen, PJH; De Smet, E; Tacken, H; Frequin, STFM; Siegers, HP; Mauser, HW; Fernandez-Fernandez, O; Leon, A; Romero, F; Alonso, A; Tamayo, J; Montalban, X; Nos, C; Pelayo, R; Tellez, N; Rio, J; Tintore, M; Arbizu, T; Romero, L; Moral, E; Martinez, S; Kappos, L; Achtnichts, L; Wilmes, S; Karabudak, R; Kurne, A; Erdem, S; SİVA, AKSEL; Saip, S; Altintas, A; Atamer, A; Eraksoy, M; Bilgili, F; Topcular, B; Giovannoni, G; Lim, ET; Lava, N; Murnane, M; Dentinger, M; Zimmerman, E; Reiss, M; Gupta, V; Scott, T; Brillman, J; Kunschner, L; Wright, D; Perel, A; Babu, A

doi:10.1056/nejmoa044396

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

Rudick R., Stuart W., Calabresi P., Confavreux C., Galetta S., Radue E., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.354, sa.9, ss.911-923, 2006 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 354 Sayı: 9
Basım Tarihi: 2006
Doi Numarası: 10.1056/nejmoa044396
Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.911-923
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an (alpha)(sub 4) integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies.